Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab

详细信息    查看全文

• 作者：Horacio Berman ; Ignasi Rodr¨ªguez-Pint¨® ; Ricard Cervera ; Nathalie Morel ; Nathalie Costedoat-Chalumeau ; Doruk Erkan ; Yehuda Shoenfeld ; Gerard Espinosa
• 关键词：Catastrophic antiphospholipid syndrome ; Refractory ; Rituximab ; Anti-CD20
• 刊名：Autoimmunity Reviews
• 出版年：2013
• 出版时间：September, 2013
• 年：2013
• 卷：12
• 期：11
• 页码：1085-1090
• 全文大小：209 K

文摘

The catastrophic variant of the antiphospholipid syndrome (APS) is characterized by thrombosis in multiple organs developing over a short period of time. First-line treatment for the catastrophic APS is the combination of anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulin. Despite this regimen, the mortality remains high and new treatment options are needed. By a systematic review of the Catastrophic APS Registry (CAPS Registry), we identified 20 patients treated with rituximab. The purpose of this study is to describe the clinical manifestations, laboratory features, and outcomes of rituximab-treated CAPS patients. In addition, the rationale for using rituximab in catastrophic APS is discussed.